Titre du projet
Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
